Contemporary management of muscle-invasive bladder cancer

Expert Review of Anticancer Therapy

Volumn 12, Issue 7, 2012, Pages 941-950

  Dall'Era, Marc A ^a   Cheng, Liang ^b   Pan, Chong Xian ^a,c,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c VA NORTHERN CALIFORNIA HEALTH CARE SYSTEM   (United States)

^d Division of Hematology and Oncology   (United States)

Author keywords

bladder urothelial carcinoma; chemotherapy; cisplatin; personalized chemotherapy; targeted therapy

Indexed keywords

CISPLATIN; DOXORUBICIN; GEMCITABINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; METHOTREXATE; VINBLASTINE;

ADJUVANT CHEMOTHERAPY; ADVANCED CANCER; BLADDER CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER INVASION; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; COMPARATIVE EFFECTIVENESS; CYSTECTOMY; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; HUMAN; LEUKOPENIA; LYMPH NODE DISSECTION; METASTASIS; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; RADIATION DOSE; RECURRENCE RISK; REVIEW; THROMBOCYTOPENIA; TRANSITIONAL CELL CARCINOMA; TRANSURETHRAL RESECTION;

ANTINEOPLASTIC AGENTS; CHEMORADIOTHERAPY, ADJUVANT; CISPLATIN; CLINICAL TRIALS AS TOPIC; CYSTECTOMY; FEMALE; HUMANS; MALE; NEOPLASM INVASIVENESS; PATIENT SELECTION; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 84864616537     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.12.60     Document Type: Review

References (69)

1. The World Cancer Report - the major findings. Cent. Eur. J. Public Health 11(3), 177-179 (2003).
2. Stewart BW. World Cancer Report 2003. IARC Press, Lyon, France (2004).
3. Johansson SL, Cohen SM. Epidemiology and etiology of bladder cancer. Semin. Surg. Oncol. 13(5), 291-298 (1997).
4. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J. Clin. 62(1), 10-29 (2012).
5. Wu XR. Urothelial tumorigenesis: A tale of divergent pathways. Nat. Rev. Cancer 5(9), 713-725 (2005).
6. Stein JP, Skinner DG. Surgical atlas. Radical cystectomy. BJU Int. 94(1), 197-221 (2004).
7. Stein JP, Lieskovsky G, Cote R et al. Radical cystectomy in the treatment of invasive bladder cancer: Long-term results in 1,054 patients. J. Clin. Oncol. 19(3), 666-675 (2001).
8. Madersbacher S, Hochreiter W, Burkhard F et al. Radical cystectomy for bladder cancer today - A homogeneous series without neoadjuvant therapy. J. Clin. Oncol. 21(4), 690-696 (2003).
9. Ghoneim MA, Abdel-Latif M, El-Mekresh M et al. Radical cystectomy for carcinoma of the bladder: 2,720 consecutive cases 5 years later. J. Urol. 180(1), 121-127 (2008).
10. Leissner J, Hohenfellner R, Thuroff JW, Wolf HK. Lymphadenectomy in patients with transitional cell carcinoma of the urinary bladder; significance for staging and prognosis. BJU Int. 85(7), 817-823 (2000).
11. Koppie TM, Vickers AJ, Vora K, Dalbagni G, Bochner BH Standardization of pelvic lymphadenectomy performed at radical cystectomy: Can we establish a minimum number of lymph nodes that should be removed? Cancer 107(10), 2368-2374 (2006).
12. Herr H, Lee C, Chang S, Lerner S. Standardization of radical cystectomy and pelvic lymph node dissection for bladder cancer: A collaborative group report. J. Urol. 171(5), 1823-1828; discussion 1827-1828 (2004).
13. Goossens-Laan CA, Gooiker GA, Van Gijn W et al. A systematic review and meta-analysis of the relationship between hospital/surgeon volume and outcome for radical cystectomy: An update for the ongoing debate. Eur. Urol. 59(5), 775-783 (2011).
14. Styn NR, Montgomery JS, Wood DP et al. Matched comparison of robotic-assisted and open radical cystectomy. Urology 79(6), 1303-1309 (2012).
15. Bloom HJ, Hendry WF, Wallace DM, Skeet RG. Treatment of T3 bladder cancer: Controlled trial of pre-operative radiotherapy and radical cystectomy versus radical radiotherapy. Br. J. Urol. 54(2), 136-151 (1982).
16. Sell A, Jakobsen A, Nerstrom B, Sorensen BL, Steven K, Barlebo H. Treatment of advanced bladder cancer category T2 T3 and T4a. A randomized multicenter study of preoperative irradiation and cystectomy versus radical irradiation and early salvage cystectomy for residual tumor. DAVECA protocol 8201. Danish Vesical Cancer Group. Scand. J. Urol. Nephrol. Suppl. 138, 193-201 (1991).
17. Skinner DG, Lieskovsky G. Contemporary cystectomy with pelvic node dissection compared to preoperative radiation therapy plus cystectomy in management of invasive bladder cancer. J. Urol. 131(6), 1069-1072 (1984).
18. Smith JA Jr, Crawford ED, Paradelo JC et al. Treatment of advanced bladder cancer with combined preoperative irradiation and radical cystectomy versus radical cystectomy alone: A Phase III intergroup study. J. Urol. 157(3), 805-807; discussion 807-808 (1997).
19. Wallace DM, Raghavan D, Kelly KA et al. Neo-adjuvant (pre-emptive) cisplatin therapy in invasive transitional cell carcinoma of the bladder. Br. J. Urol. 67(6), 608-615 (1991).
20. Coppin CM, Gospodarowicz MK, James K et al. Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or definitive radiation. The National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 14(11), 2901-2907 (1996).
21. Nanus DM, Bosl GJ. Systemic chemotherapy in the management of bladder cancer. Cancer Treat. Res. 46, 143-158 (1989).
22. Scher H, Herr H, Sternberg C et al. Neo-adjuvant chemotherapy for invasive bladder cancer. Experience with the M-VAC regimen. Br. J. Urol. 64(3), 250-256 (1989).
23. Advanced Bladder Cancer Overview Collaboration. Neoadjuvant cisplatin for advanced bladder cancer. Cochrane Database Syst. Rev. (2), CD001426 (2000).
24. Rintala E, Hannisdahl E, Fossa SD, Hellsten S, Sander S. Neoadjuvant chemotherapy in bladder cancer: A randomized study. Nordic Cystectomy Trial I. Scand. J. Urol. Nephrol. 27(3), 355-362 (1993).
25. Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: A randomised controlled trial. International collaboration of trialists. Lancet 354(9178), 533-540 (1999).
26. Griffiths G, Hall R, Sylvester R, Raghavan D, Parmar MK. International Phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: Long-term results of the BA06 30894 trial. J. Clin. Oncol. 29(16), 2171-2177 (2011).
27. Advanced Bladder Cancer Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: A systematic review and meta-analysis. Lancet 361(9373), 1927-1934 (2003).
28. Grossman HB, Natale RB, Tangen CM et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N. Engl. J. Med. 349(9), 859-866 (2003).
29. Sherif A, Holmberg L, Rintala E et al. Neoadjuvant cisplatinum based combination chemotherapy in patients with invasive bladder cancer: A combined analysis of two Nordic studies. Eur. Urol. 45(3), 297-303 (2004).
30. Chang JS, Lara PN Jr, Pan CX. Progress in personalizing chemotherapy for bladder cancer. Adv. Urol. 2012, 364919 (2012).
31. Von Der Maase H, Hansen SW, Roberts JT et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: Results of a large, randomized, multinational, multicenter, Phase III study. J. Clin. Oncol. 18(17), 3068-3077 (2000).
32. Lee CT, Madii R, Daignault S et al. Cystectomy delay more than 3 months from initial bladder cancer diagnosis results in decreased disease specific and overall survival. J. Urol. 175(4), 1262-1267; discussion 1267 (2006).
33. Freiha F, Reese J, Torti FM. A randomized trial of radical cystectomy versus radical cystectomy plus cisplatin, vinblastine and methotrexate chemotherapy for muscle invasive bladder cancer. J. Urol. 155(2), 495-499; discussion 499-500 (1996).
34. Advanced Bladder Cancer (ABC) Meta-Analysis Collaboration. Adjuvant chemotherapy for invasive bladder cancer (individual patient data). Cochrane Database Syst. Rev. (2), CD006018 (2006).
35. Millikan R, Dinney C, Swanson D et al. Integrated therapy for locally advanced bladder cancer: Final report of a randomized trial of cystectomy plus adjuvant M-VAC versus cystectomy with both preoperative and postoperative M-VAC. J. Clin. Oncol. 19(20), 4005-4013 (2001).
36. Svatek RS, Shariat SF, Lasky RE et al. The effectiveness of off-protocol adjuvant chemotherapy for patients with urothelial carcinoma of the urinary bladder. Clin. Cancer Res. 16(17), 4461-4467 (2010).
37. Loehrer PJ Sr, Einhorn LH, Elson PJ et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: A cooperative group study. J. Clin. Oncol. 10(7), 1066-1073 (1992).
38. Von Der Maase H. Gemcitabine in transitional cell carcinoma of the urothelium. Expert Rev. Anticancer Ther. 3(1), 11-19 (2003).
39. Von Der Maase H, Sengelov L, Roberts JT et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J. Clin. Oncol. 23(21), 4602-4608 (2005).
40. Sternberg CN, De Mulder PH, Schornagel JH et al. Randomized Phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924. J. Clin. Oncol. 19(10), 2638-2646 (2001).
41. Gallagher DJ, Bajorin DF. Neoadjuvant chemotherapy for the treatment of muscle-invasive bladder cancer: Argument in favor. Nat. Clin. Pract. Urol. 5(9), 484-485 (2008).
42. Fedeli U, Fedewa SA, Ward EM. Treatment of muscle invasive bladder cancer: Evidence from the National Cancer Database, 2003 to 2007. J. Urol. 185(1), 72-78 (2011).
43. Fedeli U, Novara G, Galassi C et al. Population-based analyses of radical cystectomy and urinary diversion for bladder cancer in northern Italy. BJU Int. 108(8 Pt 2), E266-E271 (2011).
44. Gandour-Edwards R, Lara PN Jr, Folkins AK et al. Does HER2/neu expression provide prognostic information in patients with advanced urothelial carcinoma? Cancer 95(5), 1009-1015 (2002).
45. Lae M, Couturier J, Oudard S, Radvanyi F, Beuzeboc P, Vieillefond A. Assessing HER2 gene amplification as a potential target for therapy in invasive urothelial bladder cancer with a standardized methodology: Results in 1005 patients. Ann. Oncol. 21(4), 815-819 (2010).
46. Stadler WM, Lerner SP, Groshen S et al. Phase III study of molecularly targeted adjuvant therapy in locally advanced urothelial cancer of the bladder based on p53 status. J. Clin. Oncol. 29(25), 3443-3449 (2011).
47. Herr HW. Transurethral resection of muscle-invasive bladder cancer: 10-year outcome. J. Clin. Oncol. 19(1), 89-93 (2001).
48. Herr HW, Bajorin DF, Scher HI. Neoadjuvant chemotherapy and bladder-sparing surgery for invasive bladder cancer:T en-year outcome. J. Clin. Oncol. 16(4), 1298-1301 (1998).
49. Solsona E, Climent MA, Iborra I et al. Bladder preservation in selected patients with muscle-invasive bladder cancer by complete transurethral resection of the bladder plus systemic chemotherapy: Long-term follow-up of a Phase 2 nonrandomized comparative trial with radical cystectomy. Eur. Urol. 55(4), 911-919 (2009).
50. Rodel C, Grabenbauer GG, Kuhn R et al. Combined-modality treatment and selective organ preservation in invasive bladder cancer: Long-term results. J. Clin. Oncol. 20(14), 3061-3071 (2002).
51. Kaufman DS, Shipley WU, Griffin PP, Heney NM, Althausen AF, Efird JT. Selective bladder preservation by combination treatment of invasive bladder cancer. N. Engl. J. Med. 329(19), 1377-1382 (1993).
52. Shipley WU, Kaufman DS, Heney NM, Althausen AF, Zietman AL. An update of selective bladder preservation by combined modality therapy for invasive bladder cancer. Eur. Urol. 33(Suppl. 4), 32-34 (1998).
53. Devere White RW, Lara PN Jr., Goldman B et al. A sequential treatment approach to myoinvasive urothelial cancer: A Phase II Southwest Oncology Group trial (S0219). J. Urol. 181(6), 2476-2480; discussion 2480-2471 (2009).
54. Housset M, Maulard C, Chretien Y et al. Combined radiation and chemotherapy for invasive transitional-cell carcinoma of the bladder: A prospective study. J. Clin. Oncol. 11(11), 2150-2157 (1993).
55. Vilmar A, Sorensen JB. Excision repair cross-complementation group 1 (ERCC1) in platinum-based treatment of non-small cell lung cancer with special emphasis on carboplatin: A review of current literature. Lung Cancer 64(2), 131-139 (2009).
56. Vilmar AC, Santoni-Rugiu E, Sorensen JB. ERCC1 and histopathology in advanced NSCLC patients randomized in a large multicenter Phase III trial. Ann. Oncol. 21(9), 1817-1824 (2010).
57. Bepler G, Kusmartseva I, Sharma S et al. RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer. J. Clin. Oncol. 24(29), 4731-4737 (2006).
58. Hoffmann AC, Wild P, Leicht C et al. MDR1 and ERCC1 expression predict outcome of patients with locally advanced bladder cancer receiving adjuvant chemotherapy. Neoplasia 12(8), 628-636 (2010).
59. Harshman LC, Bepler G, Zheng Z, Higgins JP, Allen GI, Srinivas S. Ribonucleotide reductase subunit M1 expression in resectable, muscle-invasive urothelial cancer correlates with survival in younger patients. BJU Int. 106(11), 1805-1811 (2010).
60. Matsumura N, Hara I. [The prognostic significance of human equilibrative nucleoside transporter1 (hENT1) expression in metastatic bladder cancer patients treated with gemcitabine-cisplatin based combination chemotherapy]. Hinyokika Kiyo 57(3), 157-161 (2011).
61. Takata R, Katagiri T, Kanehira M et al. Validation study of the prediction system for clinical response of M-VAC neoadjuvant chemotherapy. Cancer Sci. 98(1), 113-117 (2007).
62. Williams PD, Cheon S, Havaleshko DM et al. Concordant gene expression signatures predict clinical outcomes of cancer patients undergoing systemic therapy. Cancer Res. 69(21), 8302-8309 (2009).
63. Vinall RL, Ripoll AZ, Wang S, Pan CX, Devere White RW. MiR-34a chemosensitizes bladder cancer cells to cisplatin treatment regardless of p53-Rb pathway status. Int. J. Cancer 130(11), 2526-2538 (2012).
64. Smith SC, Havaleshko DM, Moon K et al. Use of yeast chemigenomics and COXEN informatics in preclinical evaluation of anticancer agents. Neoplasia 13(1), 72-80 (2011).
65. Henderson PT, Pan CX. Human microdosing for the prediction of patient response. Bioanalysis 2(3), 373-376 (2010).
66. Wang S, Zhang H, Malfatti M et al. Gemcitabine causes minimal modulation of carboplatin-DNA monoadduct formation and repair in bladder cancer cells. Chem. Res. Toxicol. 23(11), 1653-1655 (2010).
67. Lin TY, Zhang H, Wang S et al. Targeting canine bladder transitional cell carcinoma with a human bladder cancer-specific ligand. Mol. Cancer 10(1), 9 (2011).
68. Zhang H, Aina OH, Lam KS et al. Identification of a bladder cancer-specific ligand using a combinatorial chemistry approach. Urol. Oncol. doi:10.1016/j. urolonc.2010.06.011 (2010) (Epub ahead of print).
69. Lin T, Zhang H, Luo J et al. Multifunctional targeting micelle nanocarriers with both imaging and therapeutic potential for bladder cancer. Int. J. Nanomed. 7, 2793-2804 (2012).